Table 2.
Blood pressure and brachial artery flow-mediated dilation measures before and after acute tetrahydrobiopterin supplementation
|
Protocol 1
|
Protocol 2
|
Merged Data |
|||||
|---|---|---|---|---|---|---|---|
| Placebo | Post | Pre | Post | ΔMean P Value | Placebo/Pre | Post | |
| Systolic BP, mmHg | 123 ± 3 | 128 ± 2 | 122 ± 4 | 124 ± 2 | 0.78 | 122 ± 2 | 125 ± 3 |
| Diastolic BP, mmHg | 79 ± 2 | 80 ± 2 | 76 ± 2 | 73 ± 3 | 0.78 | 77 ± 3 | 76 ± 3 |
| Baseline diameter, mm | 4.64 ± 0.28 | 4.60 ± 0.29 | 4.68 ± 0.30 | 4.34 ± 0.35 | 0.42 | 4.66 ± 0.21 | 4.45 ± 0.23 |
| Peak diameter, mm | 4.81 ± 0.29 | 4.73 ± 0.30 | 4.77 ± 0.29 | 4.46 ± 0.36 | 0.60 | 4.78 ± 0.20 | 4.58 ± 0.24 |
| FMD, mm | 0.17 ± 0.03 | 0.13 ± 0.02 | 0.09 ± 0.02 | 0.12 ± 0.03 | 0.11 | 0.12 ± 0.02 | 0.13 ± 0.02 |
| %FMD, % | 3.25 ± 0.61 | 2.86 ± 0.42 | 2.17 ± 0.64 | 2.69 ± 0.59 | 0.28 | 2.64 ± 0.46 | 2.77 ± 0.38 |
| Time to peak, s | 78 ± 10 | 79 ± 12 | 63 ± 9 | 58 ± 11 | 0.68 | 69 ± 7 | 67 ± 8 |
| SR AUC, s−1 | 30280 ± 4428 | 37877 ± 9241 | 37588 ± 6753 | 28996 ± 3735 | 0.20 | 34456 ± 4284 | 32802 ± 4471 |
| FMD/SR AUC × 104, Δmm/s−1 | 0.10 ± 0.05 | 0.11 ± 0.05 | 0.05 ± 0.02 | 0.04 ± 0.01 | 0.43 | 0.07 ± 0.02 | 0.07 ± 0.02 |
| % FMD/SR AUC, %/s−1 | 0.21 ± 0.11 | 0.21 ± 0.12 | 0.11 ± 0.05 | 0.10 ± 0.02 | 1.00 | 0.15 ± 0.05 | 0.14 ± 0.05 |
| BF AUC, mL | 396 ± 74 | 413 ± 65 | 516 ± 115 | 377 ± 81 | 0.12 | 465 ± 72 | 392 ± 53 |
AUC, area under the curve; BF, blood flow; BH4, tetrahydrobiopterin; BP, blood pressure (supine); FMD, flow-mediated dilation; Placebo, pre, and placebo/pre, data collected without BH4 supplementation; post, data collected 4.5 h after acute BH4 supplementation (10 mg/kg); SR, shear rate; Δmean P value, the mean difference (post-pre) of each protocol was tested with unpaired Student’s t tests; data presented as means ± SE.